| 06.11.2025 14:22 | AGY | Allergy Therapeutics to explore dual listing in Hong Kong | Alliance |
| 06.11.2025 07:22 | AGY | Company to Evaluate Dual Listing on HKEX | RNS |
| 30.10.2025 07:00 | AGY | G308 Phase III Year 2 Patient Screening Starts | RNS |
| 29.10.2025 07:00 | AGY | Warrant Exercise and Paydown of Debt | RNS |
| 16.10.2025 17:07 | AGY | Allergy Therapeutics says peanut allergy vaccine trial progressing | Alliance |
| 16.10.2025 07:00 | AGY | Further progress in Phase I/IIa PROTECT trial | RNS |
| 31.07.2025 07:00 | AGY | Grass MATA MPL Publications in Allergy Journal | Reach |
| 21.07.2025 13:47 | AGY | Allergy Therapeutics shares slump as expects to post revenue decline | Alliance |
| 21.07.2025 07:00 | AGY | Trading update for the year ended 30 June 2025 | RNS |
| 11.07.2025 07:00 | AGY | PDMR Dealings | RNS |
| 13.06.2025 07:00 | AGY | Allergy Therapeutics presents findings at EAACI | Reach |
| 10.06.2025 07:04 | AGY | EAACI Early Career Research Award | Reach |
| 31.03.2025 12:24 | AGY | Allergy Therapeutics half-year loss narrows on lower expenses | Alliance |
| 31.03.2025 07:00 | AGY | Interim Results for six months ended 31 Dec 2024 | RNS |
| 27.03.2025 18:27 | AGY | Allergy Therapeutics peanut allergy vaccine trial enters final phase | Alliance |
| 27.03.2025 07:00 | AGY | Advancement to final phase of PROTECT trial | RNS |
| 03.03.2025 07:00 | AGY | New Executive Long Term Incentive Awards | RNS |
| 27.02.2025 07:00 | AGY | Presentations at 2025 AAAAI / WAO Joint Congress | Reach |
| 17.02.2025 07:00 | AGY | Grass MATA MPL Phase III data published in Allergy | RNS |
| 14.02.2025 07:00 | AGY | Grant of Options | RNS |
| 28.01.2025 21:19 | AGY | IN BRIEF: Allergy Therapeutics expects annual sales to rise on-year | Alliance |
| 28.01.2025 07:00 | AGY | Half Year Trading update | RNS |
| 22.01.2025 07:00 | AGY | PDMR Dealing and Total Voting Rights | RNS |
| 15.01.2025 07:00 | AGY | Director/PDMR Shareholding | RNS |
| 19.12.2024 13:41 | AGY | Exercise of Options and Total Voting Rights | RNS |
| 17.12.2024 16:19 | AGY | Block Listing Interim Review | RNS |
| 09.12.2024 11:30 | TSTL, TRAC, SUPR | UK shareholder meetings calendar - next 7 days | Alliance |
| 04.12.2024 07:00 | AGY | Positive Interim Data from PROTECT Trial | RNS |
| 27.11.2024 16:52 | AGY | IN BRIEF: Allergy Therapeutics treats first patient in allergy trial | Alliance |
| 27.11.2024 07:00 | AGY | First Patient Dosed in G308 Paediatric Trial | RNS |
| 25.11.2024 07:00 | AGY | Submission of MAA for Grass MATA MPL | RNS |
| 21.11.2024 07:00 | AGY | Notice of 2024 Annual General Meeting | RNS |
| 06.11.2024 11:22 | AGY | Allergy Therapeutics annual loss narrows thanks to reduced expenses | Alliance |
| 06.11.2024 07:00 | AGY | Audited Preliminary Results 2024 | RNS |
| 21.10.2024 07:00 | AGY | Commencement of Phase III Paediatric Trial | RNS |
| 16.10.2024 10:58 | AGY | Allergy Therapeutics shares surge as enters into secured loan facility | Alliance |
| 16.10.2024 07:00 | AGY | Update on funding | RNS |
| 01.10.2024 07:00 | AGY | Update on funding and preliminary results | RNS |
| 17.09.2024 07:00 | AGY | Progression of patient cohorts in PROTECT Trial | RNS |
| 27.08.2024 10:46 | AGY, GROC, BELL | AIM WINNERS & LOSERS: Belluscura shares up on expected revenue boost | Alliance |
| 27.08.2024 09:57 | AGY | Allergy Therapeutics secures cash to see it through September | Alliance |
| 27.08.2024 07:00 | AGY | Update on funding | RNS |
